Non-invasive neurostimulation devices market seen reaching $3.45 billion by 2030

The global market for non-invasive neurostimulation devices is projected to grow from $1.89 billion in 2025 to $3.45 billion by 2030, driven by rising neurological disorders, better tDCS and EMS technology, and more home-based care. North America was the largest market in 2025, while AI-enabled monitoring and portable devices are emerging as key trends.

Why it matters: - Non-invasive neurostimulation devices are gaining traction because they offer therapy without surgery for conditions such as chronic pain, depression and epilepsy. - The market’s projected 12.7% CAGR through 2030 signals sustained demand for alternatives to traditional pain management and other neurological treatments.

What happened: - The Business Research Company published its Non Invasive Neurostimulation Devices Global Market Report 2026 on Aug. 19, 2026. - The report estimates the market will rise from $1.89 billion in 2025 to $2.14 billion in 2026. - The report forecasts the market will reach $3.45 billion by 2030. - The report identifies North America as the largest regional market in 2025.

The details: - Non-invasive neurostimulation devices use external electrical currents, magnetic fields or ultrasonic waves to influence neural activity. - The devices are designed to manage neurological and psychiatric disorders without invasive surgery. - The report links growth to technological improvements in transcranial direct current stimulation, or tDCS, and electrical muscle stimulation, or EMS. - Rising chronic pain and neurological disease rates are adding to demand. - Home-based neurostimulation therapy is becoming more common. - Investment in clinical and academic research is expected to support adoption. - AI integration and smart monitoring features are expected to accelerate product development. - The report points to wider adoption of non-invasive pain management, more wearable and portable devices, and more personalized treatments as major trends. - The market also faced earlier constraints from limited device availability, reliance on traditional pain management, slow homecare adoption, limited clinical validation and slower research progress. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa in addition to North America. - The 2026 report package adds market attractiveness scoring, total addressable market analysis, company scoring matrices, Excel forecasting dashboards, market hotspot infographics, and updated graphics and tables. - Download a free sample of the report. - View the full market report.

Between the lines: - The market outlook suggests neurostimulation is moving from a niche clinical tool toward broader use in home and portable care settings. - The emphasis on AI and smart monitoring points to a shift from simple stimulation devices toward more data-driven treatment systems. - Rising dementia cases underscore the broader burden of neurological disease, which is likely to keep pressure on treatment options and diagnostics. - The UK National Health Service reported 487,432 dementia patients by June 30, 2024, up 3,155 from the previous month.

What's next: - Market growth will likely depend on whether device makers can prove clinical value, expand home use and keep improving portability and personalization. - Continued research funding and technology upgrades are expected to shape the next phase of competition in the sector. - The report suggests regional and product innovation will be key as companies target rising demand across multiple care settings.

The bottom line: - Non-invasive neurostimulation is positioned for fast growth through 2030 as aging populations, chronic neurological disease and smarter device technology expand the market.